Get the Daily Brief
Latest Biotech News
Gilead-Ouro autoimmune T-cell engager deal
Gilead Sciences agreed to acquire privately held Ouro Medicines for $2.17 billion, adding a clinical-stage BCMAxCD3 T-cell engager designed for autoimmune diseases. The acquisition centers on...
Merck and Quotient expand somatic genomics for IBD drug discovery
Merck partnered with Quotient Therapeutics to use Quotient’s somatic genomics platform for inflammatory bowel disease target discovery. Merck will pay $20 million upfront for access to the...
Kali–Sanofi trispecific KT501 autoimmune collaboration
Sanofi licensed Kali Therapeutics’ lead trispecific T-cell engager KT501 under a collaboration valued at up to $1.23 billion. Kali reported dosing the first patient in a phase Ia trial for KT501...
Karyopharm Sentry Phase 3 selinexor-myelofibrosis update ahead of potential sNDA
Karyopharm Therapeutics reported mixed topline results from its phase III Sentry trial of Xpovio (selinexor) plus ruxolitinib in front-line myelofibrosis, meeting one co-primary endpoint on spleen...
Clinical validation push for tuberculosis point-of-care diagnostics
The World Health Organization called for urgent scale-up of near point-of-care tuberculosis diagnostics, announcing updated guidance for new molecular testing approaches during World Tuberculosis...
Ocugen moves gene therapy for geographic atrophy into Phase 3
Ocugen said its gene therapy program for geographic atrophy, a form of vision loss, will move into a phase 3 trial after it reported mixed results in a smaller study. The company framed the...
Biotech startup seed funding for cryptic target discovery (dark proteome)
RyboDyn raised $10 million in seed funding to accelerate oncology target discovery by exploring the “dark proteome,” including cryptic peptides derived from non-canonical RNA sources. The company...
Crossbow Therapeutics Series B to advance T-cell engager in myeloid cancers
Crossbow Therapeutics closed a $77 million Series B round to advance its lead T-cell engager CBX-250 into later clinical completion. The company said the funding will support completion of its...
Rivia raises Series A for agentic AI to manage clinical trial data quality
Rivia raised $15 million to scale an “agentic” AI platform aimed at improving data quality and unifying clinical trial data in real time. The Swiss startup said the Series A round will be used to...
Sanofi extends $180M for Kali trispecific—double signal on KT501 clinical start
Sanofi is extending $180 million in near-term payments to Kali Therapeutics as part of a global license for KT-501, reinforcing that the company is moving quickly into next-wave T-cell engager...
Gilead snaps up Ouro to boost autoimmune bispecifics – dual pact with Galapagos
Gilead Sciences agreed to acquire Ouro Medicines in a front-loaded deal that secures OM336 (gamgertamig), a BCMA×CD3 T‑cell engager in Phase I/II for antibody‑mediated autoimmune diseases. The...
Merck inks deal with Quotient to mine somatic genomics for IBD targets
Merck Research Laboratories entered a multi‑year collaboration with Quotient Therapeutics, paying $20 million up front for access to Quotient's somatic genomics platform to discover drug targets...
Sanofi licenses Kali’s trispecific KT501 – $180M up front for autoimmune trispecific
Sanofi struck a licensing agreement with Kali Therapeutics for KT501, a CD3‑masked trispecific T‑cell engager targeting CD19, BCMA and CD3, paying $180 million in up‑front and near‑term funds plus...
Apogee’s long‑interval eczema antibody posts robust maintenance data – investors react
Apogee Therapeutics reported Phase II maintenance results showing durable skin‑clearance with its anti‑IL‑13 antibody zumilokibart (zumi) using three‑ and six‑month dosing schedules. The mid‑stage...
Karyopharm posts mixed Phase III myelofibrosis readout – FDA meeting next
Karyopharm reported Phase III Sentry results for selinexor (Xpovio) combined with ruxolitinib in first‑line myelofibrosis: the study met the spleen‑volume reduction co‑primary endpoint but missed...
Novartis shells out $2B for Synnovation’s PI3Kα program – SNV4818 acquisition
Novartis agreed to acquire Synnovation’s Pikavation subsidiary and its SNV4818 PI3Kα inhibitor program for $2 billion up front, with up to $1 billion in milestones. SNV4818 is a pan‑mutant...
AroLNPs retarget mRNA vaccines to lymph nodes – liver detargeting breakthrough
University of Pennsylvania engineers redesigned ionizable lipids to create aromatic, bioreducible lipid nanoparticles (aroLNPs) that reduce liver accumulation and preferentially deliver mRNA to...
E3 ligase atlas released to expand targeted‑protein‑degradation discovery
An international team led by Australia’s Walter and Eliza Hall Institute released a comprehensive atlas identifying 672 high‑confidence E3 ubiquitin ligases to serve as a reference for degrader...
RyboDyn raises $10M seed to mine the 'dark proteome' for cancer targets
San Diego startup RyboDyn closed a $10 million seed round to fund RyboCypher, a discovery platform that combines deep sequencing of non‑canonical RNAs with proteomics and AI to identify cryptic,...
WHO urges rapid roll‑out of near‑point‑of‑care TB tests — new testing guidance
On World Tuberculosis Day the World Health Organization issued guidance endorsing near‑point‑of‑care (nPOC) molecular NAAT diagnostics and expanded sample types (tongue swabs, pooled sputum) to...